Physician profile
Jose Rivas
NPI 1629166939
$2,506.69
in general payments reported to CMS, 2019-2025
23 companies · $93.90 in 2025
The $93.90 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $187 · 2021: $989 · 2022: $481 · 2023: $345 · 2024: $166 · 2025: $93.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.96 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $275.95 | 2022-2024 | |
| Gynesonics, INC. | $240.63 | 2021 | |
| Shield Therapeutics INC | $168.06 | 2022-2024 | Accrufer |
| Lupin INC. | $101.19 | 2019-2021 | |
| Coopersurgical, INC. | $100.51 | 2021-2024 | Summit Doppler |
| Avion Pharmaceuticals | $91.64 | 2021-2022 | |
| Hologic Sales and Service, LLC | $87.52 | 2019-2025 | Aptima |
| Myovant Sciences INC. | $76.60 | 2021-2022 | |
| Pfizer INC. | $72.74 | 2019-2023 | |
| Allergan, INC. | $59.94 | 2019 | |
| Coloplast Corp | $53.06 | 2019-2020 | |
| Daiichi Sankyo INC. | $47.49 | 2022 | |
| Therapeuticsmd, INC. | $47.03 | 2021-2022 | |
| Duchesnay USA Incorporated | $46.26 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $36.40 | 2023-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $34.97 | 2019 | |
| Astellas Pharma US INC | $31.88 | 2025 | Veozah |
| Baxter Healthcare | $24.59 | 2021 | |
| Sumitomo Pharma America, INC. | $22.02 | 2023 | Myfembree |
| Scynexis, INC. | $18.00 | 2022 | |
| Biogen, INC. | $13.88 | 2025 | Zurzuvae |
| Mission Pharmacal Company | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.